Skip to main content

CORRECTION article

Front. Oncol., 30 April 2024
Sec. Skin Cancer
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1418213

Corrigendum: Co-treatment of chloroquine and trametinib inhibits melanoma cell proliferation and decreases immune cell infiltration

This article is a correction to:

  1. Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration

    1. Read original article
Simone Degan,Simone Degan1,2Brian L. MayBrian L. May3Yingai J. JinYingai J. Jin1Manel Ben HammoudaManel Ben Hammouda1Huiying SunHuiying Sun1Guoqiang ZhangGuoqiang Zhang1Yan WangYan Wang1Detlev ErdmannDetlev Erdmann4Warren WarrenWarren Warren2Jennifer Y. Zhang,*Jennifer Y. Zhang1,5*
  • 1Department of Dermatology, Duke University Medical Center, Durham, NC, United States
  • 2Department of Chemistry, Duke University, Durham, NC, United States
  • 3Department of Surgery, Duke University, Durham, NC, United States
  • 4Division of Plastic, Maxillofacial and Oral Surgery, Duke University Medical Center, Durham, NC, United States
  • 5Department of Pathology, Duke University Medical Center, Durham, NC, United States

A Corrigendum on:
Co-treatment of chloroquine and trametinib inhibits melanoma cell proliferation and decreases immune cell infiltration

By Degan S, May BL, Jin YJ, Hammouda MB, Sun H, Zhang G, Wang Y, Erdmann D, Warren W and Zhang JY (2022). Front. Oncol. 12:782877. doi: 10.3389/fonc.2022.782877

In the published article, an author name was incorrectly written as Manel Ben Hammoda.

The correct spelling is Manel Ben Hammouda.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: MEK; melanoma, autophagy, chloroquine, MEK, tremetinib, immune cell infiltration

Citation: Degan S, May BL, Jin YJ, Ben Hammouda M, Sun H, Zhang G, Wang Y, Erdmann D, Warren W and Zhang JY (2024) Corrigendum: Co-treatment of chloroquine and trametinib inhibits melanoma cell proliferation and decreases immune cell infiltration. Front. Oncol. 14:1418213. doi: 10.3389/fonc.2024.1418213

Received: 16 April 2024; Accepted: 17 April 2024;
Published: 30 April 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Degan, May, Jin, Ben Hammouda, Sun, Zhang, Wang, Erdmann, Warren and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jennifer Y. Zhang, Jennifer.zhang@duke.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.